Financial Performance - The company reported a total revenue of RMB 1.2 billion for the first half of 2024, representing a year-on-year increase of 15%[2]. - The company's revenue for the first half of 2024 was CNY 1,366,045,101.74, a decrease of 67.19% compared to CNY 4,163,641,154.70 in the same period last year[20]. - Net profit attributable to shareholders was CNY 260,480,462.16, down 84.70% from CNY 1,702,358,148.94 year-on-year[20]. - Net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 63,520,625.14, a decline of 96.09% compared to CNY 1,623,174,034.86 in the previous year[20]. - Net cash flow from operating activities was CNY 128,547,517.42, a decrease of 22.62% from CNY 166,121,691.21 in the same period last year[20]. - The basic earnings per share decreased by 84.33% to 0.21 CNY compared to the same period last year[21]. - The diluted earnings per share also decreased by 84.33% to 0.21 CNY compared to the same period last year[21]. - The company's net profit for the first half of 2024 was CNY 384,847,977.73, a decrease from CNY 1,482,638,184.97 in the same period of 2023, representing a decline of approximately 74%[177]. - Total operating revenue for the first half of 2024 was CNY 1,366,045,101.74, a decrease of 67.2% compared to CNY 4,163,641,154.70 in the same period of 2023[172]. - Total operating costs for the first half of 2024 were CNY 1,289,398,978.35, down 42.5% from CNY 2,242,973,767.22 in the first half of 2023[172]. Market and User Growth - User data indicates a growth in the active user base by 20% compared to the same period last year, reaching 5 million users[2]. - The company expects a revenue guidance of RMB 2.5 billion for the full year 2024, reflecting a growth target of 10%[2]. - Market expansion efforts have led to a 30% increase in sales in international markets, particularly in Southeast Asia[2]. - Strategic partnerships with healthcare providers have been established, aiming to increase market penetration by 15% over the next year[2]. Research and Development - The company is investing RMB 300 million in R&D for new technologies aimed at enhancing diagnostic accuracy and speed[2]. - The company has established a comprehensive vaccine R&D technology platform, including various advanced technologies such as high-throughput expression screening and mRNA vaccine development, supporting its strategic goal to become a leader in the global vaccine industry[59]. - The company is focusing on expanding its market presence in the IVD sector, which is crucial for enhancing diagnostic accuracy and efficiency[26]. - The company has developed a hepatitis C diagnostic test that improves sensitivity by 8-10 times, significantly reducing the window period and transmission risk[34]. - The company has established multiple diagnostic technology platforms, including automated biochemical immunoassay instruments and PCR detection technology, successfully launching various in vitro diagnostic reagent products[50]. Product Development and Innovation - New product launches in the diagnostics segment contributed to a 25% increase in sales volume during the reporting period[2]. - The company has a comprehensive product range in the in vitro diagnostics field, including various testing reagents and automated diagnostic instruments[32]. - The company has achieved significant milestones in HIV diagnostics, including the launch of the world's first urine rapid test for HIV in 2019[33]. - The company has developed a new COVID-19 antigen test with a detection time of 15 minutes, achieving high sensitivity and specificity, and has received certifications from multiple international organizations, exporting to over 40 countries[35]. - The company has launched a new calcitonin product, enhancing its thyroid cancer detection portfolio, which is expected to drive growth in its thyroid function series products[35]. Financial Management and Investments - The company reported a total investment of 504,052.30 million RMB in significant non-equity projects, with an actual investment of 36,124.29 million RMB during the reporting period[91]. - The company has ongoing projects including the expansion of the nine-valent cervical cancer vaccine with a total project amount of 124,918.85 million RMB and actual investment of 10,686.76 million RMB[91]. - The company has a cash management balance of RMB 5.00 billion as of the end of the reporting period, with an authorized limit of RMB 20.00 billion[152]. - The company has a total of 1,298,942,359.86 RMB in other payables, which represents a decrease of 29.20% from the previous period[89]. - The company has received milestone payments totaling approximately 1.34 billion euros (about 1 billion RMB) from GSK for the development of a new cervical cancer vaccine[146]. Corporate Governance and Management Changes - The company appointed Jiang Zhiming as the new General Manager in January 2024, following the resignation of the previous General Manager Qiu Zixin, who will continue as Chairman[104]. - The company held its annual shareholders' meeting on April 19, 2024, to approve the election of the new board and supervisory committee[106]. - The company has undergone significant changes in its board and management structure, with multiple new appointments and resignations[105]. Environmental and Social Responsibility - The company has achieved ISO14001 and ISO50001 certifications, enhancing its environmental management performance[119]. - The company donated HPV vaccines worth 34.8 million yuan during the reporting period as part of its social responsibility initiatives[123]. - The company has implemented online monitoring for wastewater discharge at both facilities, with real-time data uploaded to regulatory platforms[118]. - The company has committed to resource reuse and recycling for large volumes of solid waste generated[120]. Risks and Challenges - The company has identified potential risks related to supply chain disruptions and is implementing measures to mitigate these risks[2]. - The company faces financial risks, including potential asset losses from R&D failures and accounts receivable risks due to budget constraints at customer organizations[101]. - The domestic in vitro diagnostic industry is experiencing intense competition, with many companies entering various segments, leading to a trend of product homogenization[98].

证券代码：603392 证券简称：万泰生物 公告编号：2024-054 北京万泰生物药业股份有限公司 关于 2024 年半年度募集资金存放 与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》《上 海证券交易所上市公司自律监管指引第 1 号——规范运作》及相关格式指引的规定，现 将北京万泰生物药业股份有限公司（以下简称"公司"）2024 年半年度募集资金存放与 使用情况专项说明如下： 一、募集资金基本情况 经中国证券监督管理委员会证监许可[2022]1098 号文核准，公司于 2022 年 6 月非 公开发行 2,586.27 万股新股，每股发行价为 135.33 元，募集资金总额为人民币 349,999.99 万元，扣除与发行有关的费用人民币 3,984.42 万元，实际募集资金净额为人民币 346,015.57 万元。该募集资金已于 2022 年 6 月 30 日到账。上述资金到账情况已经容诚 会计师事务所容诚验字[2022]5 ...

本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 证券代码：603392 证券简称：万泰生物 公告编号：2024-053 北京万泰生物药业股份有限公司 第六届监事会第三次会议决议公告 （3）在提出本意见前，未发现参与2024年半年度报告编制和审议的人员有 违反保密规定的行为。 具体内容详见公司于指定信息披露媒体披露的公司2024年半年度报告全文 及其摘要。 表决结果：同意3票、反对0票、弃权0票。 2、审议通过了《关于公司2024年半年度募集资金存放与实际使用情况的专 项报告的议案》 北京万泰生物药业股份有限公司（以下简称"公司"）于2024年8月12日以电 子邮件方式向全体监事发出第六届监事会第三次会议召开通知和会议材料。本次 会议于2024年8月22日以通讯方式召开。本次会议由公司监事会主席邢庆超先生 主持，应出席监事3人，实际出席监事3人。本次会议的出席人数、召开和表决方 式符合《公司法》等法律、法规及《公司章程》的相关规定，合法有效。 二、监事会会议审议情况 1、审议通过了《2024年半年度报告全 ...

证券代码：603392 证券简称：万泰生物 公告编号：2024-052 北京万泰生物药业股份有限公司 第六届董事会第三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 北京万泰生物药业股份有限公司（以下简称"公司"）于2024年8月12日以 电子邮件方式向全体董事发出第六届董事会第三次会议召开通知和会议材料。本 次会议于2024年8月22日以通讯方式召开。本次会议由公司董事长邱子欣先生主 持，应出席董事7人，实际出席董事7人。本次会议的出席人数、召开和表决方式 符合《公司法》等法律、法规及《公司章程》的相关规定，合法有效。 二、董事会会议审议情况 1、审议通过了《2024年半年度报告全文及其摘要》 具体内容详见公司于指定信息披露媒体披露的公司2024年半年度报告全文 及其摘要。 2、审议通过了《关于公司 2024 年半年度募集资金存放与实际使用情况的专 项报告的议案》 具体内容详见公司于指定信息披露媒体披露的《北京万泰生物药业股份有限 公司关于 2024 年半年度募集资金存放与实际使用情况 ...

证券代码：603392 证券简称：万泰生物 公告编号：2024-051 北京万泰生物药业股份有限公司 关于公司九价 HPV 疫苗拟纳入优先审评程序的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，北京万泰生物药业股份有限公司(以下简称"公司")全资子公司厦门 万泰沧海生物技术有限公司与厦门大学合作研发的"重组人乳头瘤病毒 6/11/16/18/31/33/45/52/58 型九价疫苗（大肠埃希菌）（以下简称"九价 HPV 疫 苗"）"被国家药品监督管理局药品审评中心拟纳入优先审评品种公示名单，公 示期 7 日。现将相关情况公告如下： 一、九价 HPV 疫苗主要信息 药品名称：九价人乳头瘤病毒疫苗（大肠埃希菌） 剂型：注射剂 规格：0.5m每瓶/支 二、九价 HPV 疫苗简介 宫颈癌是女性最常见的恶性肿瘤之一，由高危型 HPV 持续感染引起。宫颈 癌也是目前唯一可有效预防的癌症，最有效和经济的预防方式就是接种 HPV 疫 苗。公司本次获得受理的九价 HPV 疫苗覆盖 HPV16/18/31/33/45/52/58 七 ...

证券代码：603392 证券简称：万泰生物 公告编号：2024-050 北京万泰生物药业股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | | | | 2023/8/29，本次回购方案由时任公司董事长兼总经理邱 | | --- | --- | --- | --- | --- | | | 子欣先生提议。 | | | | | 回购方案实施期限 | 2023 年 9 月 13 日~2024 | | 年 | 9 月 12 日 | | 预计回购金额 | 万元~40,000 20,000 | 万元 | | | | 回购用途 | √减少注册资本 □用于员工持股计划或股权激励 | | | | | | □用于转换公司可转债 | | | | | | □为维护公司价值及股东权益 | | | | | 累计已回购股数 | 万股 162.9585 | | | | | 累计已回购股数占总 | 0.1285% | | | | | 股本比例 | | | | | ...

证券代码：603392 证券简称：万泰生物 公告编号：2024-049 北京万泰生物药业股份有限公司 关于使用部分闲置募集资金进行现金管理 到期赎回并继续进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 现金管理受托方：中国工商银行股份有限公司厦门海沧支行（以下简称 "工商银行"）。 现金管理金额：人民币80,000万元。 现金管理产品名称及期限：1、中国工商银行挂钩汇率区间累计型法人人 民币结构性存款产品-专户型2024年第310期P款，195天；2、中国工商银行挂钩 汇率区间累计型法人人民币结构性存款产品-专户型2024年第310期Q款，365天。 公司购买上述理财产品的具体情况详见公司于2024年1月30日在指定信息披 露媒体披露的《北京万泰生物药业股份有限公司关于使用部分闲置募集资金进行 现金管理到期赎回并继续进行现金管理的公告》（公告编号：2024-009）。 二、本次现金管理概况 （一）现金管理目的 鉴于公司募投项目均有较长的实施周期，为提高募集资金的使用效率和资金 效益，公司在确 ...

证券代码：603392 证券简称：万泰生物 公告编号：2024-048 北京万泰生物药业股份有限公司 关于全资子公司与 GSK 合作协议终止的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、基本情况 2019 年 9 月 6 日，北京万泰生物药业股份有限公司（以下简称"公司"）全 资子公司厦门万泰沧海生物技术有限公司（以下简称"万泰沧海"）与葛兰素史 克生物有限公司（以下简称"GSK"）签署了《关于新一代宫颈癌疫苗的开发和 商业化的合作协议》（以下简称"《合作协议》"）。《合作协议》约定双方基 于万泰沧海的大肠杆菌原核表达疫苗抗原技术和 GSK 的佐剂技术合作开发新一 代宫颈癌疫苗（以下简称"HPV9-AS04 候选疫苗"）。HPV9-AS04 候选疫苗的 抗原由万泰沧海负责在国内生产，GSK 则负责在海外进行疫苗佐剂及成品疫苗 的开发及生产。双方按《合作协议》约定的区域进行商业化开发。具体内容详见 公司于 2021 年 6 月 25 日在指定信息披露媒体披露的《北京万泰生物药业股份有 限公司全资子公司关于与 GSK ...

Financial Performance Expectations - The company expects a net profit attributable to shareholders for the first half of 2024 to be between 240 million and 290 million CNY, a decrease of 146.236 million to 141.236 million CNY compared to the same period last year, representing a year-on-year decline of 85.90% to 82.96%[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be between 58 million and 70 million CNY, a decrease of 156.517 million to 155.317 million CNY compared to the same period last year, representing a year-on-year decline of 96.43% to 95.69%[3]. - The total profit for the same period last year was 193.466 million CNY, with a net profit attributable to shareholders of 170.236 million CNY and a net profit after deducting non-recurring gains and losses of 162.317 million CNY[4]. Revenue Forecast - The company anticipates revenue for the second quarter of 2024 to be between 55 million and 68 million CNY, a year-on-year decrease of approximately 56.93% to 46.75%[4]. - The decline in revenue is primarily attributed to the impact of market competition and inventory reduction on the sales of the bivalent HPV vaccine, while the diagnostic segment maintains stable growth due to ongoing projects and collaborations with top hospitals[4]. Earnings Forecast Assurance - The earnings forecast has not been audited by registered accountants, and the final financial data will be disclosed in the official half-year report[3]. - The company assures that there are no significant uncertainties affecting the accuracy of this earnings forecast[4].